It has been found that BCR/ABL, a common driver mutation in CML, mediates the expression of VEGF and its transcriptional activator HIF1 through PI3K and mTOR pathways (46). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.